关键词:

中晚期肝癌, 消癌顺气汤, FAP方案, 近期疗效, 甲胎蛋白, 生活质量

Abstract:

Objective　To investigate the short-term efficacy of adjuvant therapy with Xiao'ai Shunqi Decoction combined with the FAP regimen (combination of fluorouracil, doxorubicin, and cisplatin injection) for patients with advanced liver cancer, as well as its impact on the serum level of alpha-fetoprotein (AFP) and their quality of life. Methods　A total of 104 patients with advanced liver cancer who were treated in Weihai Central Hospital from February 2021 to January 2024 were selected for the randomized controlled trial, and were divided into a treatment group and a control group by the random number table method, with 52 patients in each group. The treatment group consisted of 32 males and 20 females, with an age of (56.56±7.34) years. The control group consisted of 34 males and 18 females, with an age of (55.88±8.24) years. The treatment group were treated with Xiao'ai Shunqi Decoction and the FAP regimen, while the control group with the FAP regimen. Both groups were treated for 3 months. The objective response rates (ORR) and disease control rates (DCR) after the treatment, liver function indicators [alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), and albumin (Alb)], serum levels of AFP and carcino-embryonic antigen (CEA), and quality of life [the score of the Karnofsky Performance Status (KPS)] before and after the treatment, and the incidences of adverse reactions were compared between the two groups. χ² and t tests were used for the statistical analysis. Results　The ORR and DCR in the treatement group were higher than those in the control group [40.38% (21/52) vs. 21.15% (11/52) and 82.69% (43/52) vs. 55.77% (29/52); both P<0.05]. After the treatment, the serum levels of ALT, AST, and TBIL in the treatment group were lower than those in the control group [(46.17±9.84) U/L vs. (51.11±11.77) U/L, (41.51±7.66) U/L vs. (48.40±8.59) U/L, and (26.25±6.79) μmol/L vs. (30.17±7.73) μmol/L], and the serum level of Alb was higher [(40.82±3.35) g/L vs. (36.75±3.22) g/L] (all P<0.05). After the treatment, the serum levels of AFP and CEA in the treatment group were lower than those in the control group [(24.09±3.15) μg/L vs. (47.31±3.80) μg/L and (13.25±1.68) μg/L vs. (18.35±2.19) μg/L; both P<0.05]. After the treatment, the score of KPS in the treatment group was higher than that in the control group (81.15±4.17 vs. 74.44±4.91; P<0.05). The incidence rate of adverse reactions in the treatment group was lower than that in the control group (P<0.05). Conclusion　Adjuvant therapy with Xiao'ai Shunqi Decoction combined with the FAP regimen in the treatment of patients with advanced liver cancer can improve the short-term efficacy and their liver function and quality of life and reduce the serum level of AFP and the occurrence of adverse reactions.

Key words:

Advanced liver cancer, Xiao'ai Shunqi , Decoction, FAP regimen, Short-term efficacy, Alpha-fetoprotein, Quality of life